Synthorx to Present at the Society for Immunotherapy of Cancer (SITC) Annual Meeting

SAN DIEGO, Oct. 29, 2019 (GLOBE NEWSWIRE) — Synthorx, Inc. (NASDAQ: THOR), a clinical-stage biotechnology company developing optimized therapeutics for cancer and autoimmune disorders, today announced the presentation of three ?posters at the upcoming Society for Immunotherapy of Cancer (SITC) 34th Annual Meeting in National Harbor, MD, from November 6-10, 2019. These posters will highlight the company?s lead product candidate THOR-707 and two of its other Synthorin? cytokines for immuno-oncology.